International Medical Research Frontier

Objective To analyze the effect of Dapagliflozin in the treatment of T2DM complicated with coronary atherosclerotic heart disease. Methods From January 2021 to January 2022, 70 patients with T2DM complicated with coronary atherosclerotic heart disease in our hospital were selected, with 35 patients in each group. Patients in the control group were treated with conventional hypoglycemic drugs and atorvastatin, while those in the observation group were treated with Dapagliflozin. Results After treatment, the blood glucose, serum amino-terminal pro-brain natriuretic peptide and left ventricular end diastolic diameter of the patients in the observation group were lower than those in the control group, and the six-minute walking test was higher than that in the control group, and the total effective rate was higher than that in the control group (P < 0.05). There were no adverse reactions in the two groups (P > 0.05). Conclusion Conventional hypoglycemic drugs and lipid-lowering drugs such as atorvastatin combined with Dapagliflozin are effective in the treatment of T2DM complicated with coronary atherosclerotic heart disease, which can better control blood sugar, improve heart function, reduce amino-terminal pro-brain natriuretic peptide, and promote the exercise endurance of patients.

Dapagliflozin; T2DM; Coronary atherosclerotic heart disease